Roche, Pfizer, and Amgen's bevacizumab biosimilar in GBM Competition for Roche's, Pfizer's, and Amgen's bevacizumab biosimilar in GBM heats up.
April 14, 2022 - Amneal Pharmaceuticals 'Avastin' biosimilar receives FDA approval for bevacizumab-maly, a biosimilar to Genentech (Roche's) Avastin.
The biosimilar is a vascular endothelial growth factor inhibitor. With the FDA approval, the biosimilar will be eligible to be prescribed for the multiple indications for which the Genentech drug has been approved, including metastatic renal cell carcinoma, Stage III or IV ovarian cancer , recurrent epithelial ovarian cancer , fallopian tube, or primary peritoneal and persistent, recurrent cervical cancers.
There are two other Avastin biosimilars, Mvasi (bevacizumab-awwb), co-developed by Amgen and Allergan, and Pfizer’s Zirabev (bevacizumab-bvzr).
https://www.biospace.com/article/roche-wakes-up-to-new-competition-as-fda-approves-amneal-s-avastin-biosimilar/
In 2017 the FDA granted Roche/Genentech's VEGF inhibitor Avastin (bevacizumab) a full approval for the treatment of adult patients with glioblastoma (GBM) that progressed following prior therapy.
The new FDA approved Avastin biosimilars are now placing further pressure on Roche/Genentech's exisiting product portfolio of immuno-oncology products as external competitiors begin to carve into Roche's traditional product line sales.
[ In parallel ONCY is conducting a Phase 2 Goblet trial that is being managed by AIO, a leading academic cooperative medical oncology group based in Germany, and is designed to investigate the use of pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab in GI cancers that involve patients with metastatic pancreatic, metastatic colorectal and advanced anal cancers.]